ISSN 2415-3060 (print), ISSN 2522-4972 (online)
  • 28 of 60
Up
УЖМБС 2019, 4(6): 199–203
https://doi.org/10.26693/jmbs04.06.199
Clinical Medicine

Analysis of Indicators of Interleukin 1–Beta and Interleukin–6 in Liquidators of Accident at the Chernobyl Nuclear Power Station, Patients with Hypertensive Diseases Associated with Gastroesophageal Reflux Disease in Dynamics of Treatment

Tkachenko N. A.1 , Sinelnik V. P. 2, Protsenko E. S. 1
Abstract

The purpose of the study was to determine and evaluate the IL–1 beta and IL–6 indices in the serum of Chernobyl disaster liquidators with concomitant gastroesophageal reflux disease before and after treatment, with additional inclusion of actovegin ® Takeda Austria GmbH into the standard therapy. Material and methods. We examined 62 liquidators of accident at the Chernobyl nuclear power station with hypertensive disease associated with gastroesophageal reflux disease. There were 87.1% men and 12.9% women. Depending on the therapy performed, they were divided into the following groups: the first group included 31 patient (27 (87.0%) men, and 4 (13.0%) women), from 49 to 69 years old, mean age was 59.5 ± 0.8 years, who received standard therapy (according to the nosological form). The second group had 31 patients (27 (87.0%) males, and 4 (13.0%) females), aged from 49 to 68, whose average age was 58.5 ± 0.9 years, and who received standard therapy (according to nosological form) and additionally received the drug aktovegin 200 mg 1 time per day intravenously. Results and discussion. The results showed that in patients with hypertensive disease associated with gastroesophageal reflux disease, both in the first and second groups, after the treatment, the level of IL–1 beta was statistically significantly lower compared with the indicator before treatment, p≤ 0.001. A similar trend in the reduction of IL–6 in serum compared to the reatment before was observed in patients with hypertensive disease associated with gastroesophageal reflux disease, both in the first and second groups after treatment (p≤ 0.001). The level of IL–6 in the serum was determined in patients during hospitalization. Initially, mid–level IL–6 values were assessed for therapy in patients with hypertensive disease with concomitant gastroesophageal reflux disease, according to the control group. The average level of IL–6 was 49.74 ± 0.54 pg / ml. Depending on the gender, a statistically significant difference in the indices (p≤0.001) of both hypertensive disease patients with concomitant gastroesophageal reflux disease was also established in men and women compared with the control group; 49.94 ± 0.59 pg / ml and 48.65 ± 1.40 pg / ml, 22.94 ± 0.88 pg / ml and 19.68 ± 0.38 pg / ml. Thus, the mean IL–6 level in the control group was statistically higher than in patients with hypertensive disease and in patients with hypertensive disease with concomitant gastroesophageal reflux disease, on the whole and by gender. Conclusion. Thus, the study proved that after treatment, according to the standard procedure, and with the additional inclusion of Actovegin in patients with hypertensive disease associated with gastroesophageal reflux disease, the IL–1 beta and IL–6 statistically significantly decreased compared to the pre–treatment rates, p≤ 0.001. This was marked by a slightly better tendency towards a decrease on the background of standard treatment with the addition of Actovegin.

Keywords: liquidators of accident at the Chernobyl nuclear power station, interleukin–1 beta, interleukin–6, hypertensive disease associated with gastroesophageal reflux disease

Full text: PDF (Ukr) 201K

References
  1. Zazdravnov AA. Gipertonichna khvoroba u patsiyentiv pokhylogo viku: aktsent na sotsialni aspekty zakhvoryuvannya [Hypertension in the elderly: an emphasis on social aspects of the disease]. Semeynaya medytsyna. 2016; 2(64): 87–9. [Ukrainian]
  2. Porovskyy YaV, Tetenev FF. Komorbydnost vo vrachebnoy praktyke [Comorbidity in medical practice]. Sybyrskoe medytsynskoe obozrenye. 2015; 4: 5–10. [Russian] https://doi.org/10.20333/25000136–2015–4–5–10
  3. Andreeva EY. Osobennosty lechenyya patsyentov s gastroezofagealnoy reflyuksnoy boleznyu [Features of treatment of patients with gastroesophageal reflux disease]. Kazanskyy medytsynskyy zhurnal. 2018; 1(99): 78–84. [Russian] https://doi.org/10.17816/KMJ2018–078
  4. Parakhonskyy AP. Rol ynterleykyna–6 v serdechno–sosudystoy patologyy u bolnykh revmatoydnym artrytom [The role of interleukin–6 in cardiovascular pathology in patients with rheumatoid arthritis]. Wschodnioeuropejskie czasopismo naukowe. 2018; 2–2(18): 76–83. [Russian]
  5. Guzmán C, Hallal–Calleros C, López–Griego L, Morales–Montor J. Interleukin–6: A Cytokine with a Pleiotropic Role in the Neuroimmunoendocrine Network. The Open Neuroendocrinology Journal. 2010; 3: 152–60.
  6. Rebrova OYu. Statystycheskyy analyz medytsynskykh dannykh. Prymenenye paketa prykladnykh programm STATISTICA. M: MedyaSfera; 2006. 312 p. [Russian]
  7. Popkova TV, Novykova DS, Nasonov EL. Ynterleykyn 6 y serdechno–sosudystaya patologyya pry revmatoydnom artryte [Interleukin 6 and cardiovascular pathology in rheumatoid arthritis]. Nauchno–praktycheskaya revmatologyya. 2011; 4: 64–72. [Russian]